Patents by Inventor Giovanni Bottegoni

Giovanni Bottegoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS
    Publication number: 20210300906
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A; X; n; R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: October 21, 2019
    Publication date: September 30, 2021
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Barry John Teobald, Charlotte Fieldhouse, Nigel Alan Swain, Mark Pickworth, Giovanni Bottegoni
  • Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease
    Patent number: 9975861
    Abstract: The present invention relates to Compounds of Formula (I) and pharmaceutical compositions containing the same. It further relates to their use in the prevention or treatment of central nervous system diseases or disorders, in particular, cognitive, neurodegenerative or neuronal diseases or disorders.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: May 22, 2018
    Assignees: FONDAZIONE ISTITUTO ITAIANO DI TECNOLOGIA, ALMA MATER STUDIORUM—UNIVERSITA'DI BOLOGNA
    Inventors: Andrea Cavalli, Federica Prati, Giovanni Bottegoni, Angelo Danilo Favia, Daniela Pizzirani, Rita Scarpelli, Maria Laura Bolognesi
  • Diarylalkylamine REV-ERB antagonists and their use as medicaments
    Patent number: 9949968
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and proapoptotic agents for cancer therapy.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 24, 2018
    Assignee: Fondazione Istituto Italiano Di Tecnologia
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)
    Patent number: 9828352
    Abstract: The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar?, R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 28, 2017
    Assignees: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Giovanni Bottegoni, Alessio De Simone, Gian Filippo Ruda, Andrea Cavalli, Tiziano Bandiera, Daniele Piomelli
  • DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS
    Publication number: 20170136009
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and proapoptotic agents for cancer therapy.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 18, 2017
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • Dual Inhibitor Compounds for Use in the Treatment of Neurodegenerative Disorders and Alzheimer's Disease
    Publication number: 20170096406
    Abstract: The present invention relates to Compounds of Formula (I) and pharmaceutical compositions containing the same. It further relates to their use in the prevention or treatment of central nervous system diseases or disorders, in particular, cognitive, neurodegenerative or neuronal diseases or disorders.
    Type: Application
    Filed: June 12, 2015
    Publication date: April 6, 2017
    Inventors: Andrea Cavalli, Federica Prati, Giovanni Bottegoni, Angelo Danilo Favia, Daniela Pizzirani, Rita Scarpelli, Maria Laura Bolognesi
  • Diarylalkylamine REV-ERB antagonists and their use as medicaments
    Patent number: 9611245
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: April 4, 2017
    Assignee: Fondazione Istituto Italiano Di Tecnologia
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS
    Publication number: 20160237057
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.
    Type: Application
    Filed: October 9, 2014
    Publication date: August 18, 2016
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR)
    Publication number: 20160194296
    Abstract: The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar?, R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.
    Type: Application
    Filed: July 10, 2014
    Publication date: July 7, 2016
    Inventors: Giovanni BOTTEGONI, Alessio DE SIMONE, Gian Filippo RUDA, Andrea CAVALLI, Tiziano BANDIERA, Daniele PIOMELLI
  • INHIBITORS OF ANANDAMIDE TRANSPORT AND THEIR THERAPEUTIC USES
    Publication number: 20140163034
    Abstract: Nucleic acid and polypeptide sequences corresponding to FLAT, a partly cytosolic variant of the intracellular anandamide-degrading enzyme, fatty acid amide hydrolase-1 (FAAH-1), are provided. FLAT lacks amidase activity but binds the endocannibinoid anandamide and facilitates its transport into cells. A chemical scaffold for the inhibition of anandamide transport is identified. Compositions of the invention prevent anandamide internalization in vitro, interrupt anandamide deactivation in vivo, and cause profound CB1 cannabinoid receptor-mediated analgesia in a mouse model of inflammatory pain. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the modulation of anandamide transport would be of benefit.
    Type: Application
    Filed: November 25, 2013
    Publication date: June 12, 2014
    Applicants: IIT-Istituto Italiano di Tecnologia, The Regents of the University of California
    Inventors: Daniele Piomelli, Jin Fu, Giovanni Bottegoni, Andrea Cavalli, Tiziano Bandiera